Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome. 2012

Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Geert Grooteplein Zuid 8, 6525, GA, Nijmegen, the Netherlands. h.prinsen@onco.umcn.nl

BACKGROUND Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and disabling fatigue that is medically unexplained and lasts longer than 6 months. Although it is possible to effectively treat CFS, the nature of the underlying physiology remains unclear. Various studies have sought evidence for an underlying disturbance in immunity. The aim of this study was to compare the humoral and cellular immune responses upon influenza vaccination in CFS patients and healthy controls. RESULTS Identical antibody titers were observed in CFS patients and healthy controls. Patients and controls demonstrated similar seroprotection rates against all three virus-strains of the influenza vaccine, both pre- and post-vaccination. Functional T cell reactivity was observed in both CFS patients and healthy controls. CFS patients showed a non-significant, numerically lower cellular proliferation at baseline compared to controls. Vaccination induced a significant increase in cellular proliferation in CFS patients, but not in healthy controls. Cytokine production and the number of regulatory T cells were comparable in patients and controls. CONCLUSIONS The humoral and cellular immune responses upon influenza vaccination were comparable in CFS patients and healthy controls. Putative aberrations in immune responses in CFS patients were not evident for immunity towards influenza. Standard seasonal influenza vaccination is thus justified and, when indicated, should be recommended for patients suffering from CFS.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations

Related Publications

Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
October 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
December 2017, The Journal of allergy and clinical immunology,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
April 1980, Annals of internal medicine,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
January 1983, Nephron,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
August 2012, Oncology letters,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
October 1979, American journal of veterinary research,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
November 2007, Pharmacotherapy,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
March 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
March 2006, Vaccine,
Hetty Prinsen, and I Jolanda M de Vries, and Ruurd Torensma, and Jeanette M Pots, and Sasja F Mulder, and Carla M L van Herpen, and Lammy D Elving, and Gijs Bleijenberg, and Foekje F Stelma, and Hanneke W M van Laarhoven
January 2021, Rheumatology (Oxford, England),
Copied contents to your clipboard!